ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 163 filers reported holding ACHILLION PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 0.46 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $397,000 | +21.8% | 65,813 | -27.3% | 0.06% | -1.5% |
Q3 2019 | $326,000 | +27.3% | 90,554 | -5.3% | 0.07% | +22.2% |
Q2 2019 | $256,000 | -0.4% | 95,598 | +10.0% | 0.05% | -90.1% |
Q1 2019 | $257,000 | +69.1% | 86,904 | -9.3% | 0.55% | +2003.8% |
Q4 2018 | $152,000 | -73.9% | 95,817 | -39.5% | 0.03% | -56.7% |
Q3 2018 | $582,000 | -24.2% | 158,277 | -41.7% | 0.06% | -91.2% |
Q2 2018 | $768,000 | -21.1% | 271,426 | +3.5% | 0.68% | -19.5% |
Q1 2018 | $973,000 | +178.8% | 262,284 | +116.3% | 0.84% | +92.7% |
Q4 2017 | $349,000 | +0.3% | 121,264 | +56.6% | 0.44% | +831.9% |
Q3 2017 | $348,000 | +7.7% | 77,433 | +10.1% | 0.05% | -2.1% |
Q2 2017 | $323,000 | +10.6% | 70,350 | +1.3% | 0.05% | -7.7% |
Q1 2017 | $292,000 | +12.7% | 69,450 | +10.6% | 0.05% | -32.5% |
Q4 2016 | $259,000 | +18.8% | 62,792 | +133.3% | 0.08% | -26.7% |
Q3 2016 | $218,000 | +3.8% | 26,915 | 0.0% | 0.10% | -32.7% |
Q2 2016 | $210,000 | +6.1% | 26,915 | +4.7% | 0.16% | -42.9% |
Q1 2016 | $198,000 | – | 25,711 | – | 0.27% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 13,633,220 | $56,305,000 | 7.98% |
BVF INC/IL | 2,423,300 | $10,008,000 | 2.01% |
EMORY UNIVERSITY | 454,102 | $1,875,000 | 1.85% |
DAFNA Capital Management LLC | 196,500 | $812,000 | 0.71% |
Orbimed Advisors | 13,107,200 | $54,133,000 | 0.69% |
RTW INVESTMENTS, LP | 286,285 | $1,182,000 | 0.44% |
Marcus Capital, LLC | 100,000 | $413,000 | 0.44% |
Rock Springs Capital Management LP | 1,375,000 | $5,679,000 | 0.38% |
Spark Investment Management LLC | 978,600 | $4,041,000 | 0.33% |
Bellevue Group AG | 240,000 | $991,000 | 0.20% |